Partner Content
Medicines adherence: Overcoming pharma’s biggest barrier to treatment success
Adherence to medications – defined as the extent to which patients take medications as prescribed by their healthcare providers –…
Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective
By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged…
The power of joint procurement: Analysing cross-border initiatives in Benelux and the Nordics
In April, the pilot-level Nordic Pharmaceutical Forum (NPF) initiative, representing Finland, Iceland, Norway, Sweden, and Denmark, released an updated strategy…
Clinical trials in Ukraine: Ensuring supply chain continuity during war
The war in Ukraine has had a significant impact on clinical trials in Europe, exacerbating supply chain delays that were…
Avrobio to sell cystinosis gene therapy to Novartis for $87.5m
Avrobio has announced a deal to sell its investigational haematopoietic stem cell (HSC) gene therapy programme, designed to treat cystinosis,…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
US FDA approves Krystal Biotech’s Vyjuvek for DEB
The US Food and Drug Administration (FDA) has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis…
Myeloid raises funds to support lead cell therapy programme
Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase…
Virtual clinical trials: How digital tech has improved clinical trial accrual rates
For clinical trial participants, dropping out of trials is often due to the distances from their homes to the trial…
KSQ and Takeda expand partnership for new tumour-intrinsic targets
KSQ Therapeutics has announced the expansion of its immuno-oncology strategic partnership with Takeda for new tumour-intrinsic targets. This partnership will…
AGC Biologics rolls out new viral vector platforms
AGC Biologics has introduced the BravoAAV and ProntoLVV viral vector platforms that offer quick clinical and commercial production and release…